Exicure, Inc. (XCUR) |
|
1.45 -0.015 (-1.02%)
|
02-03 13:14 |
|
Open: |
1.47 |
Pre. Close: |
1.465 |
|
High:
|
1.5799 |
Low:
|
1.42 |
|
Volume:
|
74,754 |
Market Cap:
|
7(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 1:51:01 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 2.07 One year: 2.42 |
| Support: |
Support1: 1.34  Support2: 1.07 |
| Resistance: |
Resistance1: 1.77 Resistance2: 2.07 |
| Pivot: |
1.4 |
| Moving Average: |
MA(5): 1.42 MA(20): 1.39
MA(100): 1.34 MA(250): 2.88 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 72.2 %D(3): 71 |
| RSI: |
RSI(14): 56.6 |
| 52-week: |
High: 10.17 Low: 0.11 |
| Average Vol(K): |
3-Month: 249 (K) 10-Days: 25 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ XCUR ] has closed below upper band by 25.1%. Bollinger Bands are 65% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.49 - 1.5 |
1.5 - 1.5 |
|
Low:
|
1.4 - 1.41 |
1.41 - 1.42 |
|
Close:
|
1.45 - 1.46 |
1.46 - 1.47 |
|
Company Description |
|
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. |
Headline News |
Sun, 29 Jan 2023
Dogecoin (DOGE) Knock-Off Suddenly Jumps 50% - U.Today
Mon, 23 Jan 2023
Should You Accumulate Exicure Inc (XCUR) Stock Monday Morning? - InvestorsObserver
Tue, 10 Jan 2023
Curate (XCUR): How Risky is It Tuesday? - InvestorsObserver
Thu, 22 Dec 2022
Healthcare Stocks Moving Thursday: ISO, PRQR, ORIC, XCUR, SINT, HTGM, ATNF, NMTC - InvestorsObserver
Wed, 14 Dec 2022
AbbVie, Ipsen Terminate Partnerships With Exicure As Bankruptcy Concern Looms - Yahoo Finance
Wed, 29 Jun 2022
Exicure implements reverse-stock-split to get back Nasdaq compliance - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
-19 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
1.0113e+008 (%) |
|
% Held by Institutions
|
3.22e+006 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.884e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-0.29 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
453.8 |
|
Return on Equity (ttm)
|
-56.8 |
|
Qtrly Rev. Growth
|
3.48e+006 |
|
Gross Profit (p.s.)
|
-9.85 |
|
Sales Per Share
|
1.84 |
|
EBITDA (p.s.)
|
-6.36 |
|
Qtrly Earnings Growth
|
-4.938e+007 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-5.13 |
|
Price to Sales
|
0.78 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
106160 |
|
Forward Dividend
|
142120 |
|
Dividend Yield
|
7321380% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
